Yazar "Unal, Aysun" seçeneğine göre listele
Listeleniyor 1 - 2 / 2
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Doublecortin-like kinase 1 levels and oxidant status in Alzheimer's disease(Cukurova Univ, Fac Medicine, 2017) Guzel, Savas; Yildiz, Ozlem; Unal, Aysun; Kiziler, Ali Riza; Gulyasar, Tevfik; Guzel, Eda Celik; Fidan, CigdemPurpose: Alzheimer disease (AD) is a progressive neurodegenerative disease that affects the neurons in various parts of the central nervous system. Recently discovered protein Doublecort like kinase-1 (DCLK-1) is one of the microtubule-associated protein. Our goal is to investigate the relationship of the role of the DCLK-1 in AD disease and oxidative stress. Material and Methods: The study included Alzheimerdisease- diagnosed 60 patients admitted to the clinic with memory disorders, and 30 healthy subjects. In the serum of patient and control group, DCLK-1, tau protein and zinc levels were measured. To assess the presence of oxidative stress, malondialdehyde (MDA), protein carbonyl group (PCG), protein thiol groups (PTG), glutathione (GSH) and catalase levels were detected. Dementia level was staged with Mini-Mental State Examination (MMSE) and Dementia Clinical Staging Scale (CDR). Results: Serum DCLK-1 and tau levels were determined significantly higher in AD compared to the control group). In the group with AD, levels of MDA, and PCG levels were significantly higher and GSH, catalase levels were determined significantly lower. DCLK-1 and MDA levels were determined significantly higher in the group with severe AD compared to the group with mild AD. In AD group, a positive correlation between DCLK-1 and, CDR and MDA; and negative correlation was found between MMSE and B12 vitamin Conclusions: The presence of a relation with increase in DCLK1 levels in AD and risk factors shows that it can be a new marker in assessing the disease.Öğe Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting(Elsevier Sci Ltd, 2023) Altunan, Bengu; Unal, Aysun; Efendi, Husnu; Koseoglu, Mesrure; Terzi, Murat; Kotan, Dilcan; Tamam, YusufBackground: Follow-on disease modifying therapies (FO-DMTs) do not always require Phase III studies. There are concerns that cheaper FO-DMTs are only used to reduce healthcare costs. However, the well-being of people with MS (pwMS) should be a priority. We aimed to evaluate the efficacy, safety and treatment satisfaction of one of the FO-Fingolimod (FTY) used in Turkey with the approval of Turkish Ministry of Health.Methods: PwMS under FTY were recruited from 13 centers and real-world data and answers of satisfaction and adherence statements of pwMS on FTY treatment were analyzed.Results: Data of 239 pwMS were obtained. The duration of FTY treatment was 2.5 & PLUSMN; 0.8 (1-4) years in pwMS who were included in the study and whose treatment continued for at least one year. Significant decreases in annual relapse rate (p < 0.001), Expanded Disability Status Scale (p < 0.001) and neuroimaging findings (p < 0.001) were observed. While 64% of the patients were satisfied and 71.5% were found to adherent with this FO-FTY.Conclusion: This multicenter retrospective study found that the efficacy, safety and treatment adherence of a prescribed FO-FTY were consistent with the results of real-world studies. Studies including real-world data may provide guidance to address issues related to FO-FTY use.